The Breyanzi REMS program and the Abecma REMS program were established due to the risk of cytokine release syndrome and neurologic toxicities.

Novo Nordisk end their partnership with Hims & Hers; update to Vizamyl labeling; autoinjector approved for pediatrics with lupus nephritis; psilocybin shows promise in treatment-resistant depression; ...

Enflonsia is an extended half-life RSV fusion glycoprotein neutralizing monoclonal antibody that is designed to provide durable protection through 5 months.

About 1 in every 150 people infected develops severe symptoms that can affect the brain, spinal cord and nerves.

The phase 3 trial evaluated fenfluramine when used as an adjunctive therapy for the treatment of uncontrolled seizures in children and adults aged 1 year to 35 years with CDD.

The scientist named on the slide, Robert Berman of the University of California-Davis, says he never wrote such a paper.

Michelle Bulls, director of the NIH’s Office of Policy for Extramural Research Administration, said no more grant cancellations should move forward.